missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Phospho-PERK (Thr982) Polyclonal Antibody
Rabbit Polyclonal Antibody
Brand: Invitrogen™ PA537773
This item is not returnable.
View return policy
Description
A suggested positive control for IHC is human prostate carcinoma.
EIF2AK3 (PERK) is one of 4 kinases that specifically phosphorylate Ser51 of translation initiation factor eIF2-alpha in response to various environmental stresses, leading to a decrease in protein sythesis. In the case of EIF2AK3, signaling is initiated by misfolded proteins in the ER. Defects in EIF2AK3 are the cause of Wolcott-Rallison syndrome (WRS), also known as multiple epiphyseal dysplasia with early-onset diabetes mellitus. WRS is a rare autosomal recessive disorder, characterized by permanent neonatal or early infancy insulin-dependent diabetes and, at a later age, epiphyseal dysplasia, osteoporosis, growth retardation and other multisystem manifestations, such as hepatic and renal dysfunctions, mental retardation and cardiovascular abnormalities.
Specifications
| Phospho-PERK (Thr982) | |
| Polyclonal | |
| Unconjugated | |
| EIF2AK3 | |
| 2.7.11.1; AI427929; EIF2AK3; eukaryotic translation initiation factor 2 alpha kinase 3; eukaryotic translation initiation factor 2-alpha kinase 3; HsPEK; OTTHUMP00000207187; OTTHUMP00000207188; Pancreatic eIF2-alpha kinase; PEK; Perk; PRKR-like endoplasmic reticulum kinase; WRS | |
| Rabbit | |
| Antigen affinity chromatography | |
| RUO | |
| 9451 | |
| -20°C | |
| Liquid |
| Immunohistochemistry (Paraffin) | |
| 1 mg/mL | |
| PBS with 50% glycerol and 0.02% sodium azide; pH 7.4 | |
| Q9NZJ5 | |
| EIF2AK3 | |
| Peptide sequence around phosphorylation site of threonine 982(A-R-H(p)-T-G) derived from Human PEK/PERK. | |
| 100 μL | |
| Primary | |
| Human | |
| Antibody | |
| IgG |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction